Evelo Biosciences Inc

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 --   CAMBRIDGE, Mass., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today provided an update on recent positive regulatory interactions on the EDP1815 Phase 2 trial design, resulting in a reduction in the overall development plan timeline to registration.

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

Industry veteran brings expertise in manufacturing, R&D, and operations from leadership roles at Novartis, Eli Lilly, and Moderna Industry veteran brings expertise in manufacturing, R&D, and operations from leadership roles at Novartis, Eli Lilly, and Moderna

Evelo Biosciences Appoints Juan Andres to Board of Directors

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q3 2019 Results - Earnings Call Transcript

Evelo Biosciences (EVLO) CEO Simba Gill on Q2 2019 Results - Earnings Call Transcript

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q1 2019 Results - Earnings Call Transcript

News for Evelo Biosciences Inc Stock (EVLO)